Acrivon Therapeutics, Inc. Common Stock
USD1.68
+0.10 (+6.33%)
CEO
Peter Blume-Jensen
IPO Date
2022-11-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$1.58
Prev. Close
$1.58
Day Low
$1.58
Day High
$1.68
52W Low
$1.15
52W High
$3.56
Market Cap
$0.05B
Volume
0.27M
| 20,275 |
| $1.52 |
| 22 Jun 2026 | Shacham Sharon | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | Palani Santhosh | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | Magovcevic-Liebisch Ivana | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | DiRocco Derek | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | BAUM CHARLES M | director | A-Award | Acquired | 20,275 | $1.52 |
| 26 May 2026 | Blume-Jensen Peter | director, officer: President and CEO | F-InKind | Disposed | 13,729 | $1.79 |
| 20 May 2026 | Mirza Mansoor Raza | Chief Medical Officer | A-Award | Acquired | 38,817 | $0.00 |
| 20 May 2026 | Miller Mary | Chief Legal Officer | A-Award | Acquired | 49,830 | $0.00 |